Ownership and insider activity for Editas Medicine, Inc. (EDIT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Ory Daniel Scott | A-Award | 950,000 | $2.9M |
| 2026-09-08 | Ory Daniel Scott | |||
| 2026-09-03 | Burkly Linda | S-Sale | 709 | $2K |
| 2026-09-03 | Parison Amy | S-Sale | 453 | $1K |
| 2026-09-03 | O'Neill Gilmore Neil | S-Sale | 5,124 | $16K |
| 2026-08-06 | Ellinor Patrick Thomas II | A-Award | 103,400 | $300K |
| 2026-08-06 | Ellinor Patrick Thomas II | |||
| 2026-08-03 | Parison Amy | S-Sale | 678 | $2K |
| 2026-07-28 | Burkly Linda | S-Sale | 4,928 | $13K |
| 2026-06-17 | Connaughton Bernadette | A-Award | 51,700 | $132K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $185.3M | $146.6M | $134.8M | $238.2M | $139.7M | $203.5M | $141.5M | $123.7M | $131.5M | $146.6M |
| Short-term Investments | 0 | $182.5M | $234.2M | $219.0M | $262.4M | $296.3M | $202.8M | $199.5M | $138.4M | 0 |
| Receivables | $88000 | $679000 | $30000 | $418000 | $6.0M | $267000 | $5.1M | $10.2M | $16.3M | $15.2M |
| Inventory | $1.7M | $1.9M | $2.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $187.2M | $332.2M | $374.8M | $463.8M | $419.1M | $507.3M | $356.8M | $340.8M | $289.3M | $163.9M |
| Property, Plant & Equipment | $40.4M | $39.4M | $40.2M | $39.6M | $39.1M | $43.3M | $59.2M | $45.7M | $47.1M | $19.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $229.2M | $373.3M | $420.4M | $508.9M | $572.6M | $677.5M | $514.3M | $499.2M | $341.6M | $186.5M |
| Accounts Payable | $4.6M | $4.0M | $5.3M | $5.8M | $6.4M | $5.0M | $9.5M | $8.3M | $5.5M | $2.6M |
| Short-term Debt | $10.0M | $7.5M | 0 | 0 | 0 | 0 | 0 | $12.0M | 0 | $11.0M |
| Total Current Liabilities | $33.1M | $36.7M | $35.9M | $60.0M | $58.2M | $46.9M | $60.1M | $63.2M | $77.2M | $46.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $53.6M |
| Total Liabilities | $94.6M | $165.2M | $184.2M | $246.4M | $179.0M | $123.8M | $153.6M | $150.1M | $207.3M | $159.2M |
| Retained Earnings | -$185.5M | -$305.9M | -$416.3M | -$549.2M | -$665.2M | -$857.7M | -$1.08B | -$1.23B | -$1.47B | -$1.63B |
| Total Equity | $134.6M | $208.1M | $236.2M | $262.4M | $393.6M | $553.6M | $360.7M | $349.1M | $134.3M | $27.3M |
| Total Debt | $35.1M | $33.4M | $32.4M | $29.1M | $26.1M | $26.4M | $43.9M | $48.5M | $35.0M | $76.7M |
| Net Debt | -$150.2M | -$295.7M | -$336.5M | -$428.1M | -$376.0M | -$473.5M | -$300.3M | -$274.6M | -$234.9M | -$69.9M |
| Working Capital | $154.1M | $295.5M | $338.9M | $403.9M | $360.9M | $460.4M | $296.6M | $277.6M | $212.1M | $117.6M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 3.19 |
Profitability
| Return on Equity | -196.63% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -31.15% |
| Gross Margin | 56.90% |
| Operating Margin | -174.71% |
| Net Margin | -157.32% |
Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL
Explore sector: Healthcare · Biotechnology
More sections of EDIT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks